{"id":69312,"date":"2026-07-03T14:46:47","date_gmt":"2026-07-03T06:46:47","guid":{"rendered":"https:\/\/flcube.com\/?p=69312"},"modified":"2026-07-03T14:46:49","modified_gmt":"2026-07-03T06:46:49","slug":"cspc-pharmaceuticals-megalith-subsidiary-enters-1-77-billion-sirna-collaboration-with-astrazeneca-for-novel-rnai-therapeutics","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69312","title":{"rendered":"CSPC Pharmaceutical&#8217;s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CSPC Pharmaceutical Group Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1093:HKG\">HKG: 1093<\/a>) announced that its subsidiary <strong>Megalith<\/strong> has entered into a strategic collaboration with <strong>AstraZeneca<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NYSE\">NYSE: AZN<\/a>) focused on the discovery and development of novel <strong>small interfering RNA (siRNA) drug candidates<\/strong>. The partnership targets two jointly selected therapeutic areas and includes potential total consideration of up to <strong>$1.77 billion<\/strong>, comprising upfront, milestone, and royalty payments.<\/p>\n\n\n\n<h2 id=\"h-deal-structure-amp-financial-terms\" class=\"wp-block-heading\">Deal Structure &amp; Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Amount<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD 30 million<\/td><td>Paid upon deal execution<\/td><\/tr><tr><td><strong>R&amp;D Milestone Payments<\/strong><\/td><td>Up to USD 540 million<\/td><td>Contingent on preclinical and clinical development achievements<\/td><\/tr><tr><td><strong>Sales Milestone Payments<\/strong><\/td><td>Up to USD 1.2 billion<\/td><td>Based on commercial performance thresholds<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Low-to-mid single-digit %<\/td><td>Tiered royalties on annual net sales of licensed products<\/td><\/tr><tr><td><strong>Total Potential Value<\/strong><\/td><td>USD 1.77 billion<\/td><td>Maximum aggregate consideration across all payment types<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-collaboration-framework\" class=\"wp-block-heading\">Collaboration Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Two jointly selected targets for siRNA drug development<\/td><\/tr><tr><td><strong>Project Scope<\/strong><\/td><td>One initial project plus one additional project<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Discovery through preclinical candidate compounds (PCCs)<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Multiple therapeutic areas with significant unmet medical need<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>Megalith&#8217;s proprietary siRNA discovery and optimization capabilities<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-option-rights\" class=\"wp-block-heading\">Strategic Option Rights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Option Trigger:<\/strong> AstraZeneca&#8217;s review of comprehensive PCC data package<\/li>\n\n\n\n<li><strong>Exclusive Rights:<\/strong> Development, manufacturing, and commercialization within licensed territory<\/li>\n\n\n\n<li><strong>Territory Scope:<\/strong> Global rights subject to standard licensing arrangements<\/li>\n\n\n\n<li><strong>Decision Timeline:<\/strong> Standard industry evaluation period following PCC nomination<\/li>\n\n\n\n<li><strong>Post-Option Responsibilities:<\/strong> AstraZeneca assumes full development and commercialization costs<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-strategic-rationale\" class=\"wp-block-heading\">Market Context &amp; Strategic Rationale<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>RNAi Therapeutics Market<\/strong><\/td><td>Rapidly expanding segment with proven clinical and commercial success<\/td><\/tr><tr><td><strong>China Biotech Innovation<\/strong><\/td><td>Demonstrates maturation of Chinese biopharmaceutical R&amp;D capabilities<\/td><\/tr><tr><td><strong>Big Pharma Partnership Trend<\/strong><\/td><td>Increasing reliance on external innovation for novel modalities<\/td><\/tr><tr><td><strong>CSPC Strategic Positioning<\/strong><\/td><td>Validates Megalith&#8217;s siRNA platform as competitive globally<\/td><\/tr><tr><td><strong>Financial Impact<\/strong><\/td><td>Significant non-dilutive funding to support broader R&amp;D pipeline<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-forward-outlook\" class=\"wp-block-heading\">Forward Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The collaboration positions CSPC Pharmaceutical at the forefront of China&#8217;s emerging RNA interference therapeutics sector, leveraging AstraZeneca&#8217;s global development expertise and commercial infrastructure. For AstraZeneca, the partnership provides access to innovative siRNA candidates from a proven Chinese discovery platform, complementing its existing oncology and specialty care portfolios.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Megalith will retain responsibility for initial discovery and preclinical development, with the potential for substantial milestone payments driving continued investment in its siRNA technology platform. The deal structure reflects confidence in the therapeutic potential of the selected targets while providing AstraZeneca with flexibility to advance only the most promising candidates through its global development pipeline.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This transaction represents one of the largest RNAi-focused collaborations involving a Chinese biotechnology company and underscores the growing recognition of China&#8217;s capabilities in next-generation therapeutic modalities.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding partnership arrangements, financial considerations, development timelines, and commercial expectations. Actual results may differ due to risks including research outcomes, regulatory decisions, milestone achievement, and market dynamics in the RNAi therapeutics space.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u77f3\u836f\u521b\u65b0\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u4e0e\u963f\u65af\u5229\u5eb7\u7b7e\u7f72\u5408\u4f5c\u3001\u9009\u62e9\u6743\u53ca\u6388\u6743\u534f\u8bae\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u77f3\u836f\u521b\u65b0\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u4e0e\u963f\u65af\u5229\u5eb7\u7b7e\u7f72\u5408\u4f5c\u3001\u9009\u62e9\u6743\u53ca\u6388\u6743\u534f\u8bae\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-37cca8ca-3ce5-4c8c-97a3-4246c2697ad9\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u77f3\u836f\u521b\u65b0\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u4e0e\u963f\u65af\u5229\u5eb7\u7b7e\u7f72\u5408\u4f5c\u3001\u9009\u62e9\u6743\u53ca\u6388\u6743\u534f\u8bae\u7684\u516c\u544a.pdf\">\u77f3\u836f\u521b\u65b0\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u4e0e\u963f\u65af\u5229\u5eb7\u7b7e\u7f72\u5408\u4f5c\u3001\u9009\u62e9\u6743\u53ca\u6388\u6743\u534f\u8bae\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u77f3\u836f\u521b\u65b0\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u4e0e\u963f\u65af\u5229\u5eb7\u7b7e\u7f72\u5408\u4f5c\u3001\u9009\u62e9\u6743\u53ca\u6388\u6743\u534f\u8bae\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-37cca8ca-3ce5-4c8c-97a3-4246c2697ad9\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its subsidiary Megalith has entered into a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[130,171,855,4621,64],"class_list":["post-69312","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-astrazeneca","tag-cspc-pharmaceutical","tag-hkg-1093","tag-nyse-azn","tag-rnai-aso"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC Pharmaceutical&#039;s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its subsidiary Megalith has entered into a strategic collaboration with AstraZeneca (LSE: AZN) focused on the discovery and development of novel small interfering RNA (siRNA) drug candidates. The partnership targets two jointly selected therapeutic areas and includes potential total consideration of up to $1.77 billion, comprising upfront, milestone, and royalty payments.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69312\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC Pharmaceutical&#039;s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its subsidiary Megalith has entered into a strategic collaboration with AstraZeneca (NYSE: AZN) focused on the discovery and development of novel small interfering RNA (siRNA) drug candidates. The partnership targets two jointly selected therapeutic areas and includes potential total consideration of up to $1.77 billion, comprising upfront, milestone, and royalty payments.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69312\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-03T06:46:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-03T06:46:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69312#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69312\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC Pharmaceutical&#8217;s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics\",\"datePublished\":\"2026-07-03T06:46:47+00:00\",\"dateModified\":\"2026-07-03T06:46:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69312\"},\"wordCount\":482,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AstraZeneca\",\"CSPC Pharmaceutical\",\"HKG: 1093\",\"NYSE:\u202fAZN\",\"RNAi \\\/ ASO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69312#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69312\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69312\",\"name\":\"CSPC Pharmaceutical's Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-03T06:46:47+00:00\",\"dateModified\":\"2026-07-03T06:46:49+00:00\",\"description\":\"CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its subsidiary Megalith has entered into a strategic collaboration with AstraZeneca (LSE: AZN) focused on the discovery and development of novel small interfering RNA (siRNA) drug candidates. The partnership targets two jointly selected therapeutic areas and includes potential total consideration of up to $1.77 billion, comprising upfront, milestone, and royalty payments.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69312#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69312\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69312#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC Pharmaceutical&#8217;s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC Pharmaceutical's Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its subsidiary Megalith has entered into a strategic collaboration with AstraZeneca (LSE: AZN) focused on the discovery and development of novel small interfering RNA (siRNA) drug candidates. The partnership targets two jointly selected therapeutic areas and includes potential total consideration of up to $1.77 billion, comprising upfront, milestone, and royalty payments.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69312","og_locale":"en_US","og_type":"article","og_title":"CSPC Pharmaceutical's Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics","og_description":"CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its subsidiary Megalith has entered into a strategic collaboration with AstraZeneca (NYSE: AZN) focused on the discovery and development of novel small interfering RNA (siRNA) drug candidates. The partnership targets two jointly selected therapeutic areas and includes potential total consideration of up to $1.77 billion, comprising upfront, milestone, and royalty payments.","og_url":"https:\/\/flcube.com\/?p=69312","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-03T06:46:47+00:00","article_modified_time":"2026-07-03T06:46:49+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69312#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69312"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC Pharmaceutical&#8217;s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics","datePublished":"2026-07-03T06:46:47+00:00","dateModified":"2026-07-03T06:46:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69312"},"wordCount":482,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AstraZeneca","CSPC Pharmaceutical","HKG: 1093","NYSE:\u202fAZN","RNAi \/ ASO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69312#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69312","url":"https:\/\/flcube.com\/?p=69312","name":"CSPC Pharmaceutical's Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-03T06:46:47+00:00","dateModified":"2026-07-03T06:46:49+00:00","description":"CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its subsidiary Megalith has entered into a strategic collaboration with AstraZeneca (LSE: AZN) focused on the discovery and development of novel small interfering RNA (siRNA) drug candidates. The partnership targets two jointly selected therapeutic areas and includes potential total consideration of up to $1.77 billion, comprising upfront, milestone, and royalty payments.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69312#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69312"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69312#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC Pharmaceutical&#8217;s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69312"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69312\/revisions"}],"predecessor-version":[{"id":69314,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69312\/revisions\/69314"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}